SetPoint Medical is pioneering bioelectronic medicine to offer patients and providers a potentially safe and cost-effective approach for treatment of chronic autoimmune diseases.

SetPoint Medical has raised more than $80 million to date in series A through D financing rounds with top tier VC and strategic investors.

SetPoint Medical’s revolutionary, miniaturized microregulator is currently undergoing clinical studies in the United States for rheumatoid arthritis under FDA’s Investigational Device Exemption. In parallel, the company has conducted an additional successful proof-of-concept study in Crohn’s disease as well as promising pre-clinical research in multiple sclerosis. SetPoint Medical expects to commercialize its bioelectronic medicine platform following FDA approval of its device.

Cutting-Edge Research Services